Where does Palvella Therapeutics's cash flow data come from?

Every line is extracted from Palvella Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

	FY'25	FY'24	FY'23	FY'22
Net income	-$41.72M-177%	-$15.08M-181%	$18.69M+156%	-$33.28M+27.2%
Stock-based compensation	$6.4M+671%	$830K—	——	$4.4M-15.6%
Change in accounts payable	——	$2.24M+200%	-$2.25M+46.6%	-$4.21M-160%
Change in accrued liabilities	——	——	-$1.18M+70.6%	-$4.01M-141%
Change in other assets	-$1.36M-191%	$1.5M+651%	-$273K-120%	$1.36M-56.9%
Loss on extinguishment of debt	——	$0-100%	$23.1M—	——
Change in operating lease liabilities	——	——	——	——
Net cash from operating activities	-$25.01M-131%	-$10.84M—	——	-$59.93M-682%
Net cash from investing activities	——	——	——	——
Proceeds from issuance of common stock	$763K—	$0—	——	$6.92M-81.9%
Other financing activities	——	——	——	——
Payment of debt issuance costs	——	——	——	——
Net cash from financing activities	——	$87.09M—	——	$7.21M-87.8%
Effect of exchange rate changes on cash	——	$3K—	$0—	——
Net increase (decrease) in cash	-$25.62M-133%	$76.58M+980%	-$8.7M+89.0%	-$79.13M—
Accretion (Amortization) of Discounts and Premiums, Investments	——	——	——	——
Accounts payable	——	$2.24M+200%	-$2.25M+46.6%	-$4.21M-160%
Accrued expenses and other liabilities	——	——	-$1.18M+70.6%	-$4.01M-141%
Increase Decrease In Derivative Liabilities	$394K-37.8%	$633K+231%	-$485K—	——
Operating lease liabilities	——	——	——	——
Increase (Decrease) in Prepaid Expense and Other Assets	-$1.36M-191%	$1.5M+651%	-$273K-120%	$1.36M-56.9%
Payments Of Stock Issuance Costs	$154K—	$0—	——	——
Cash Acquired From Reverse Merger Transaction	$0-100%	$13.8M—	$0—	——
Increase Decrease In Operating Lease Liability	——	——	——	——
Increase Decrease In Research And Development Tax Credit Receivables	-$2.11M-206%	$1.98M—	$0—	——
Non Cash Lease Operating Expense	——	$0—	——	——
Noncash Interest Expense Income Royalty Agreement	——	$3.89M+162%	-$6.27M—	——
Payment For Contingent Consideration Liability Financing Activities	——	——	——	——
Payments Of Merger Related Costs Financing Activities	——	$2.47M—	$0—	——
Payments Of Transaction Costs Associated With Pipe Financing	$0-100%	$2.54M—	$0—	——
Transaction Costs Related To Reverse Merger Included In Accounts Payable And Accrued Expenses	$0-100%	$1.27M—	$0—	——

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

Where does Palvella Therapeutics's cash flow data come from?: Every line is extracted from Palvella Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.